Pfizer inks $5.3B Paxlovid supply deal with US, adding to its huge pandemic revenue haul

Pfizer, already flush with revenue from its BioNTech-partnered COVID-19 vaccine, has officially locked up a deal to sell its coronavirus antiviral hopeful to the U.S. for several billion dollars.

The U.S. will pay $5.29 billion for 10 million courses of Pfizer's investigational antiviral Paxlovid, provided it passes muster at the FDA. Under the deal, Pfizer would start delivering doses this year and wrap up in 2022, the company said Thursday.